Exiqon A/S
INTERIM REPORT FOR THE PERIOD 1 JANUARY – 30 SEPTEMBER 2013 (UNAUDITED)

Exiqon A/S 

29.10.2013 08:30
---------------------------------------------------------------------------

Exiqon A/S (NASDAQ OMX Copenhagen: 'EXQ') today announced results for the first
nine month of 2013: 

In summary (DKK million)        Q3 2013  Q3 2012      Q3 YTD     Q3 YTD  Outlook
                                                        2013       2012     2013
--------------------------------------------------------------------------------
Revenue                            29.8     30.1        94.9       83.1    ~ 130
--------------------------------------------------------------------------------
Gross profit                       19.6     19.2        59.1       46.8         
--------------------------------------------------------------------------------
EBITDA                              0.1      2.7        -1.5       -6.0   > 0
--------------------------------------------------------------------------------
Net profit                         -1.7     -0.7        -7.4      -13.0         
--------------------------------------------------------------------------------
Cash flows from operating           2.3     -4.0        -1.1      -10.2   > 0
 activities                                                                     
--------------------------------------------------------------------------------
EPS                               -0.05    -0.02       -0.20      -0.37         
--------------------------------------------------------------------------------

Financial highlights

  -- In the first nine months of 2013 revenue increased 14% to DKK 94.9 million
     (DKK 83.1 million) with research product sales and services (excluding OEM)
     increasing 24% to DKK 78.9 (DKK 63.9 million). In the third quarter of 2013
     research product sales and services (excluding OEM) increased 17% to DKK
     26.5 million (DKK 22.5 million) with research product sales and services
     (excluding OEM) in North America increasing 44%.
  -- In the first nine months of 2013 operating expenses increased 9% to DKK
     64.2 million (DKK 58.6 million) due to new hiring's in Sales & Marketing.
     In the third quarter of 2013 operating expenses increased 12% to DKK 20.7
     million (DKK 18.5 million) due to DKK 1.8 million in one-time costs
     expensed under R&D.
  -- In the first nine months of 2013 EBITDA improved to DKK -1.5 million (DKK -
     6.0 million) including non-cash cost of share-based payment of DKK 2.2
     million (DKK 2.1 million). In the third quarter of 2013, EBITDA was
     affected by one-time costs and decreased to DKK 0.1 million (DKK 2.7
     million) including non-cash cost of share-based payment of DKK 0.7 million
     (DKK 0.9 million).
  -- In the first nine months of 2013 the net result was DKK -7.4 million (DKK
     -13.0 million). EPS amounted to DKK -0.20 (DKK -0.37). In the third quarter
     of 2013, net result was DKK -1.7 million (DKK -0.7 million).
  -- Cash flow from operating activities was DKK -1.1 million (DKK -10.2
     million) in the first nine months of 2013.
  -- The financial outlook for 2013 is unchanged.

Operational highlights

  -- On 3 September 2013, Exiqon announced an extension to the LNA(TM) longRNA
     GapmeR product line with the launch of a novel on-line bioinformatics tool
     for the design of custom LNA(TM)-gapmer antisense oligonucleotides for
     specific and efficient inhibition of mRNA and lncRNA. The new on-line LNA(TM)
     gapmer design tool provides a valuable addition to Exiqon's fast growing
     product line for functional analysis by allowing scientists to effortlessly
     design optimal LNA(TM) gapmers through a simple and intuitive interface.
  -- Exiqon is establishing new laboratory facilities for its upcoming offering
     of Next Generation Sequencing services and work is progressing as planned
     with first sales expected by first quarter of 2014.

In a comment, CEO Lars Kongsbak said: 'I'm very pleased with the strong
performance in North America which indicates that the changes implemented over
the past year are starting to pay-off. I'm also very pleased to see that our
Next Generation Sequencing effort which we established on the back of the bond
financing is on track for launch early 2014'. 

See the full interim report in the attached PDF or at
www.exiqon.com/investor/portal. 

Additional information
Lars Kongsbak, CEO, phone +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, phone +45 4566 0888 (cell: +45 4090 2131)
News Source: NASDAQ OMX



29.10.2013 Dissemination of a Corporate News, transmitted by DGAP - 
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Exiqon A/S
              
               
              Denmark
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         DK0060077758
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------